Paragon 28 Management

Management criteria checks 2/4

Paragon 28's CEO is Albert DaCosta, appointed in Jan 2012, has a tenure of 12.25 years. total yearly compensation is $3.23M, comprised of 21.7% salary and 78.3% bonuses, including company stock and options. directly owns 13.3% of the company’s shares, worth €90.50M. The average tenure of the management team and the board of directors is 3.8 years and 2.8 years respectively.

Key information

Albert DaCosta

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage	21.7%
CEO tenure	12.3yrs
CEO ownership	13.3%
Management average tenure	3.8yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Albert DaCosta's remuneration changed compared to Paragon 28's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$3m	US$701k	-US$48m
Sep 30 2023	n/a	n/a	-US$67m
Jun 30 2023	n/a	n/a	-US$68m
Mar 31 2023	n/a	n/a	-US$67m
Dec 31 2022	US$5m	US$650k	-US$67m
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$29m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$5m	US$615k	-US$14m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	US$4m
Mar 31 2021	n/a	n/a	US$4m
Dec 31 2020	US$933k	US$588k	US$3m

Compensation vs Market: Albert's total compensation ($USD3.23M) is above average for companies of similar size in the German market ($USD1.29M).

Compensation vs Earnings: Albert's compensation has been consistent with company performance over the past year.

CEO

Albert DaCosta (49 yo)

12.3yrs

Tenure

US$3,232,421

Compensation

Mr. Albert DaCosta is Co-Founder of Paragon 28, Inc. and serves as Chief Executive Officer, President and Director since 2012. Mr. DaCosta is a veteran in the foot and ankle industry with over 18 years of...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Albert DaCosta	Co-Founder	12.3yrs	US$3.23m	13.3% $ 90.5m
Kristina Wright	Independent Interim CFO & Director	no data	US$220.00k	0.012% $ 79.4k
Robert McCormack	General Counsel & Secretary	less than a year	US$1.40m	no data
Matthew Jarboe	Chief Commercial Officer	5.8yrs	US$1.53m	0.26% $ 1.8m
Andrew Hill	Executive Vice President of Research & Development	no data	US$1.31m	0.10% $ 705.1k
Jeff Sears	Vice President of Operations	2.3yrs	no data	no data
Erik Mickelson	Chief Accounting Officer & Controller	2yrs	no data	0.0054% $ 36.9k
Matt Brinckman	Senior Vice President of Strategy & Investor Relations	2.3yrs	no data	no data
Michelle Missal	VP & Chief Compliance Officer	5.3yrs	no data	no data
John Shumaker	Executive Vice President of Sales - U.S.	4.3yrs	no data	no data
Brendan Shook	Executive VP of Marketing & Medical Education	no data	no data	no data
Hans Kestler	Executive Vice President of International	3.8yrs	no data	no data

3.8yrs

Average Tenure

43.5yo

Average Age

Experienced Management: 7GQ's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Albert DaCosta	Co-Founder	12.3yrs	US$3.23m	13.3% $ 90.5m
Kristina Wright	Independent Interim CFO & Director	2.3yrs	US$220.00k	0.012% $ 79.4k
B. Johnson	Independent Director	2.3yrs	US$212.50k	0.022% $ 150.7k
Stephen Newman Oesterle	Independent Director	3.3yrs	US$210.00k	0.019% $ 130.9k
Thomas Schnettler	Lead Independent Director	3.8yrs	US$245.00k	0.018% $ 119.2k
Quentin Blackford	Independent Director	1.7yrs	US$220.00k	0.019% $ 126.6k
Meghan Scanlon	Independent Director	2yrs	US$345.00k	0.0072% $ 48.9k
Alf Grunwald	Independent Director	7.2yrs	US$210.00k	0.026% $ 175.8k

2.8yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 7GQ's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Paragon 28 Management

Management criteria checks 2/4

Key information

Recent management updates

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Co-Founder recently bought €234k worth of stock

Jason Edie Step Down from the Position of Chief Technology Officer of Paragon 28, Inc

High number of new directors

Insider recently sold €1.1m worth of stock

Recent updates

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc. to Report Q1, 2024 Results on May 08, 2024

Paragon 28, Inc. Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler®? R3INFORCE™? Extraosseous Repair System

New major risk - Financial position

Co-Founder recently bought €234k worth of stock

Full year 2023 earnings released: US$0.58 loss per share (vs US$0.88 loss in FY 2022)

Paragon 28, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Paragon 28, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Paragon 28, Inc. Launches Precision®? Mis Bunion System Offering Surgeons A Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions

Paragon 28, Inc. Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures

New minor risk - Shareholder dilution

Paragon 28, Inc. Launches the Mister Tendon™ Harvester System – the First and Only Minimally Invasive Harvesting System for Fhl and Fdl Tendon Transfer Procedures

Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures

Paragon 28, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Paragon 28, Inc. Announce the Launch of the Grappler Knotless Anchor System and Bridgeline Tape

Paragon 28, Inc. Launches Beast Cortical Fibers

Third quarter 2023 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2022)

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2023

New minor risk - Share price stability

Paragon 28, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Paragon 28®, Inc. Receives FDA Approval for Ide Feasibility Study of Its Smart Total Talus™ System for Use in Conjunction with the Apex 3D™ Total Ankle Replacement System

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022)

Paragon 28, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System

Jason Edie Step Down from the Position of Chief Technology Officer of Paragon 28, Inc

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.12 loss in 1Q 2022)

Paragon 28, Inc. Provides Revenue Guidance for the Year 2023

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.26 loss in FY 2021)

Paragon 28, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Paragon 28, Inc. has completed a Follow-on Equity Offering in the amount of $110.5 million.

Paragon 28, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full-Year Ended December 31, 2022

Paragon 28, Inc. Enters Settlement Agreement with Stryker Corp

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 3Q 2021)

Paragon 28, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year of 2022

Insider recently sold €1.1m worth of stock

Paragon 28, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Paragon 28, Inc. Announces Board Changes

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.05 loss in 2Q 2021)

Paragon 28, Inc. Revises Revenue Guidance for the Full Year 2022

Paragon 28, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Paragon 28, Inc.(NYSE:FNA) dropped from Russell 2500 Value Index

Key Executive recently sold €355k worth of stock

Paragon 28, Inc. Launches Monkey Rings™ Circular External Fixation System

Key Executive recently sold €420k worth of stock

Paragon 28, Inc. Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.021 loss in 1Q 2021)

Paragon 28, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new directors

Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair

Paragon 28, Inc. Launches R3ACT™ Stabilization System for Ankle Injuries

Paragon 28, Inc. to Report Q1, 2022 Results on May 09, 2022

Paragon 28, Inc. Announces Executive Changes

High number of new directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age